Pharmaceutical UK health technology assessor the National Institute for Health and Care Excellence (NICE) has recommended Vumerity (diroximel fumarate), a next-generation, oral fumarate, from US biotech Biogen for the treatment of adults living with active relapsing-remitting multiple sclerosis (RRMS) in England, Wales, and Northern Ireland. 13 April 2022